血小板生成素
血小板生成素
免疫学
血小板生成素受体
血小板减少性紫癜
罗米普洛斯蒂姆
埃尔特罗姆博帕格
作者
Zhangyuan Kong,Ping Qin,Shan Xiao,Hai Zhou,Hong Li,Renchi Yang,Xiaofan Liu,Jianmin Luo,Zhichun Li,Guochao Ji,Zhongguang Cui,Yusheng Bai,Yuxia Wu,Linlin Shao,Jun Peng,Jun Ma,Ming Hou
出处
期刊:Blood
[American Society of Hematology]
日期:2017-08-31
卷期号:130 (9): 1097-1103
被引量:44
标识
DOI:10.1182/blood-2017-01-761262
摘要
The aim of this study was to determine the safety and efficacy of recombinant human thrombopoietin (rhTPO) for the management of immune thrombocytopenia (ITP) during pregnancy. Pregnant patients with ITP were enrolled in the study if they had a platelet count less than 30 × 109/L, were experiencing bleeding manifestations, had failed to respond to corticosteroids and/or intravenous immunoglobulin (IVIG), and had developed refractoriness to platelet transfusion. Thirty-one patients received rhTPO at an initial dose of 300 U/kg once daily for 14 days. Twenty-three patients responded (74.2%), including 10 complete responders (>100 × 109/L) and 13 responders (30-100 × 109/L). It appears that rhTPO ameliorated the bleeding symptoms remarkably, even in the nonresponders. rhTPO was well tolerated. Dizziness, fatigue, and pain at an injection site were reported in 1 patient each. No congenital disease or developmental delays were observed in the infants in a median follow-up of 53 (range, 39-68) weeks. In conclusion, rhTPO is a potentially safe and effective treatment choice for patients with ITP during pregnancy. Our work has paved the way for further study on the clinical application of rhTPO and other thrombopoietic agents for the management of ITP during pregnancy. This study is registered at www.clinicaltrials.gov as NCT02391272.
科研通智能强力驱动
Strongly Powered by AbleSci AI